Gravitas Medical Inc. Announces SECOND FDA Breakthrough Device Designation for its Entarik System; Pediatric Patients to Benefit from Enteral Nutrition Innovation!
Gravitas Medical to accelerate development and approval processes to expedite pediatric patient access to Entarik’s revolutionary technology.
SAN FRANCISCO, Dec. 13, 2023 /PRNewswire-PRWeb/ — Gravitas Medical Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted a second Breakthrough Device Designation to Entarik, the innovative Enteral Feeding System. This award allows Gravitas Medical to accelerate development and approval processes to expedite pediatric patient access to Entarik’s revolutionary technology.
